Home
Conditions
Lymphatic Diseases

Clinical trial condition

Lymphatic Diseases

Explore clinical trials studying Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

8,967 public trials 1,828 recruiting studies

Refine in advanced search Browse all conditions

Lymphatic Diseases trial results

Active, Not Recruiting

Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

NCT03422731

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hematologic Diseases, +12 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Active, Not Recruiting

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

NCT01860937

Conditions: Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +15 more
Locations: Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital Boston, Massachusetts, United States

Memorial Sloan Kettering Cancer Center New York, United States

View Trial Details

Active, Not Recruiting

A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia

NCT01683279

Conditions: B Cell Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations: Seattle Children's Hospital Seattle, Washington, United States

View Trial Details

Active, Not Recruiting

Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

NCT05363800

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +20 more
Locations: Henan cancer Hospital Zhengzhou, Henan, China

Sheng Jing Hospital of China Medical University Shengyang, Liaoning, China

Zhejiang University School of Medicine The First Affiliated Hospital Hangzhou, Zhejiang, China

View Trial Details

Active, Not Recruiting

Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

NCT05723055

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations: Karmanos Cancer Institute Detroit, Michigan, United States

Huntsman Cancer Institute at the University of Utah Salt Lake City, Utah, United States

View Trial Details

Active, Not Recruiting

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

NCT05053659

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States

View Trial Details

Active, Not Recruiting

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

NCT03186118

Conditions: CD 19+ Acute Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations: Seattle Children's Hospital Seattle, Washington, United States

View Trial Details

Active, Not Recruiting

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

NCT04722172

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations: Memorial Sloan Kettering Basking Ridge (All protocol activities) Basking Ridge, New Jersey, United States

Hackensack Meridian Health (Data collection only) Hackensack, New Jersey, United States

Memorial Sloan Kettering Monmouth (All protocol activities) Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (All protocol activities) Montvale, New Jersey, United States

View Trial Details

Active, Not Recruiting

CAR-T Cell Therapy Targeting to CD19 for R/R ALL

NCT03919240

Conditions: Acute Lymphoblastic Leukemia With Failed Remission, Disease Attributes, Hematologic Diseases, +13 more
Locations: The Fisrt Affiliated Hospital of Soochow University Suzhou, Jiangsu, China

View Trial Details

Active, Not Recruiting

Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

NCT05651178

Conditions: Central Nervous System Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +10 more
Locations: The Second Affiliated Hospital of Nanchang University Nanchang, Jiangxi, China

View Trial Details

Lymphatic Diseases

Lymphatic Diseases trial results

Related conditions